Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers: A Proof of Concept Study

NCT06365970 is registered in ClinicalTrials.gov with Ibrahim Halil Sahin as lead sponsor.

NCT NCT06365970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06365970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers: A Proof of Concept Study
Lead sponsor
Ibrahim Halil Sahin
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2025
Completion date
January 31, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

mmr-d/msi-h colorectal cancers